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Abstract
Bone morphogenetic proteins (BMPs) play important roles in cardiovascular development. However,
how BMP-signaling pathways regulate cardiac gene expression is less clear. We have previously
identified myocardin as a cardiac and smooth muscle–specific transcriptional cofactor for serum
response factor (SRF). Myocardin potently activates target gene expression by tethering with SRF
bound to SRF-responsive elements, the CArG box. Here, we show that Smad1, an effector of the
BMP-signaling pathway, synergistically activates myocardin-dependent cardiac gene expression.
Interestingly, the CArG box is necessary and sufficient to mediate such synergy, whereas no obvious
Smad-binding element appears to be involved. Consistent with their functional interaction, we find
that myocardin and Smad1 proteins interact directly. Furthermore, myocardin protein levels were
dramatically increased by BMP-2 treatment in cardiomyocytes. These findings suggest myocardin
participates in a BMP signaling–dependent cardiac gene transcriptional program.
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Myocardin is a serum response factor (SRF) cofactor expressed in cardiac and smooth muscle
(SM) cell lineages.1 Although myocardin lacks intrinsic DNA-binding ability, it forms a stable
ternary complex with SRF to potently activate muscle-specific genes through the consensus
sequence CC(A/T)6GG, known as a CArG box.1–3 In addition to activating cardiac gene
expression and the cardiogenesis program, myocardin is also a potent transactivator for smooth
muscle cell (SMC) differentiation and SM-related gene expression.1,4–13 Despite the
significant role of myocardin in controlling muscle gene expression, upstream signaling
pathways that regulate myocardin activity remain unknown.
Bone morphogenetic proteins (BMPs) are growth and differentiation factors of the
transforming growth factor (TGF)-β superfamily.14 Signaling by this superfamily is mediated
by Smad proteins. There are three classes of Smads: receptor-regulated Smads (R-Smads), co-
Smad (Smad4), and inhibitory Smads. To date, 3 R-Smads (Smad1, -5, and -8) participate in
BMP signaling.15 Once activated, R-Smads form a heteromeric complex with Smad4 that
translocates into the nucleus to regulate expression of BMP-responsive genes.15 Smad proteins
bind DNA relatively weakly, but are strongly recruited to specific target genes by interacting
with other transcription factors.15
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BMPs and downstream BMP signaling effectors are essential for cardiovascular development.
16–21 However, it is clear BMP signaling alone is insufficient to activate the cardiac gene
program because BMP-signaling pathway components are expressed in a wide range of tissues
and cell types outside of cardiac muscle. Indeed, the ability of BMP signaling to commit
specific mesodermal cells to a cardiac fate requires the interpretation of BMP signaling in a
cell type–specific mechanism. How BMP signaling interacts with cardiac transcriptional
networks is largely unknown. In light of the role of BMP signaling and myocardin in
cardiovascular development, we investigated whether BMP signaling might regulate
myocardin-mediated cardiac gene expression.
In this report, we show that Smad1 synergistically activates myocardin-dependent cardiac gene
expression. Interestingly, the CArG box is necessary and sufficient for such synergy, whereas
no obvious Smad-binding elements (SBEs) are involved. Consistent with their functional
interaction, myocardin and Smad1 proteins physically interact. Myocardin transactivity was
repressed by Smad7, an inhibitory Smad, and enhanced by constitutively activated activin
receptor-like kinase (ALK)-3, a type I BMP receptor. Furthermore, myocardin protein
expression was dramatically induced by BMP-2 treatment in cardiomyocytes. These findings




Myocardin and SRF-expression plasmids have been described.1,22 Myocardin C-terminal
deletion mutants (M1, M2, and M3) were cloned into a pcDNA expression vector with a N-
terminal Myc tag. Myocardin and Smad1 cDNAs were cloned into pGEX-KG vector to
generate glutathione S-transferase (GST) fusion proteins. Smad1, Smad4, Smad7, and
constitutively activated (Q233D) ALK3 (ALK3 QD) expression plasmids have been described.
23–26 Smad1 cDNA was subcloned into pM1 vector to make GAL4-Smad1 fusion protein.
Cell Culture and Luciferase Reporter Assays
α-Cardiac actin (α-CA),27 myosin light chain 2V (MLC2V),28 α-myosin heavy chain (α-
MHC),1 and atrial natriuretic factor (ANF)1 promoter luciferase reporters have been described.
The Nkx2.5 promoter and SBE mutations have been described and were cloned into pGL3.29
Truncated ANF luciferase reporters were generated by cloning the −406, −226, and −115 to
+70 regions of the ANF promoter into pGL3. The −115 ANF reporter was further truncated by
deleting the −5 to +70 region. The ANF SBE mutation (−5 to −2) was generated by site-directed
mutagenesis. COS7 cells were cultured as described.1 Neonatal rat cardiomyocytes prepared
as described.30 Reporter assays were conducted in triplicate at least 2 times in 12-well plates.
Transfections were performed with either Fugene6 (Roche) or Lipofectamine (Invitrogen)
reagents. Unless otherwise indicated, 100 ng of reporter and 200 ng of activator plasmids were
used. A cytomegalovirus-lacZ reporter was used as an internal control to normalize for
transfection efficiencies, and total amount of DNA per well was kept constant by adding the
corresponding amount of empty expression vector. Statistical analysis was performed using
the Student’s t test; comparisons were considered significant where P<0.05.
GST Protein Pull-Down Assays
GST alone, GST-Smad1, and GST-myocardin proteins were expressed and purified as
described and used for in vitro binding assays.12 Smad1 and myocardin proteins were in vitro
translated (Promega) and [35S] methianone labeled. Pull-downs were performed by incubating
radiolabeled proteins with bead-bound GST fusion proteins in buffer (20 mmol/L Tris [pH
7.3], 150 mmol/L NaCl, 0.5% Nonidet P-40, and protease inhibitors) for 2 hours at 4°C,
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followed by 3 washes in the same buffer. Samples were analyzed by SDS-PAGE and
autoradiography.
Communoprecipitation and Western Blotting Assays
COS7 cells were transfected with Myc-myocardin and Flag-Smad1 plasmids in 10-cm plates.
After 48 hours posttransfection, whole-cell extracts were prepared in 1 mL of PBS buffer
containing 1 mmol/L EDTA, 0.5% Triton X-100, 1 mmol/L phenylmethylsulfonyl fluoride,
and protease inhibitors. Extracts were cleared by 10 000g centrifugation for 10 minutes,
incubated with anti-Flag M2 affinity gel resin (Sigma) for 2 hours at 4°C and then washed 3
times in the same buffer, and samples were subsequently analyzed by SDS-PAGE and Western
blot analysis using anti-Myc (1:2500; A-14, Santa Cruz Biotechnology) or anti-Flag (1:2500;
M2, Sigma) antibodies.
Electrophoretic Mobility-Shift Assay
Electrophoretic mobility-shift assays (EMSAs) were performed essentially as described using
the c-fos CArG probe.31 Complementary oligonucleotides were annealed and labeled using
Klenow polymerase and [α-32P]dCTP. Labeled probe was incubated with in vitro translated
SRF, Myc-tagged myocardin, and/or Smad1 proteins in gel-shift buffer. Antibody supershift
experiments were performed with anti-SRF (G-20, Santa Cruz Biotechnology) or anti-Myc.
DNA–protein complexes were separated by gel electrophoresis on a 5% nondenaturing
polyacrylamide gel and visualized by autoradiography.
BMP-Response Assay
After serum starving overnight, cardiomyocytes cultured in 10-cm plates were treated with (or
without treatment in control) 20 ng/mL recombinant BMP-2 (R&D Systems) for 48 hours, then
harvested in 200 μL lysis buffer composed of PBS containing 0.5% Triton X-100, 1 mmol/L
EDTA, 1 mmol/L phenylmethylsulfonyl fluoride, and protease inhibitors. Twenty microliters
of lysate were loaded onto SDS-PAGE for Western blot analysis. Antibodies used were anti-
myocardin (1:1000; sc-21559, Santa Cruz Biotechnology); anti–myocyte enhancer factor 2
(MEF2) (1:1000; sc-313, Santa Cruz Biotechnology); anti-SRF (1:2500; sc-335, Santa Cruz
Biotechnology); anti–α-actinin (1:2500; sc-17829, Santa Cruz Biotechnology); and anti–β-
tubulin (1:5000; T-4026, Sigma).
Results
Synergistic Activation of Cardiac Promoters by Myocardin and Smad Proteins
Smad1 is a downstream effector of BMP signaling that mediates target gene transcription; we,
therefore, tested whether myocardin and Smad1 might activate cardiac gene expression in a
cooperative manner. Whereas myocardin strongly activated the ANF promoter luciferase
reporter (Figure 1A),1 coexpression of myocardin and Smad1 synergistically activated this
reporter in COS7 cells. In contrast, Smad1 by itself did not significantly activate the ANF
reporter (Figure 1A). Myocardin and Smad1 also synergistically activated the ANF reporter in
cardiomyocytes (Figure 1G). Similarly, myocardin and Smad1 synergistically activated all
other cardiac promoter reporters tested (Figure 1B through 1E). Because Smad1 is known to
heterodimerize with Smad4, we investigated the effects of Smad4 on myocardin/Smad1
synergy and found that Smad4 further increased myocardin/Smad1 activation (Figure 1E).
To rule out the possibility that the myocardin/Smad1 synergy observed was an indirect effect
mediated through SRF, we tested whether myocardin and GAL4-Smad1 fusion protein could
activate a GAL4-dependent luciferase reporter (UAS-luciferase). GAL4-Smad1 and
myocardin activated the UAS-luciferase reporter in a dose-dependent manner (Figure 1F).
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Similarly, Smad1 synergized with GAL4-myocardin fusion protein to activate the UAS-
luciferase reporter (data not shown). These results suggest myocardin/Smad1 synergy is
directly mediated by myocardin and Smad1 interaction. Together, we conclude BMP-signaling
mediator Smad1 dramatically enhances myocardin transactivation of cardiac promoters.
CArG Box Is Necessary and Sufficient to Mediate Myocardin and Smad1 Synergy
Deletion analysis of the ANF promoter was performed to determine the minimal region required
for myocardin/Smad1 functional interaction. Coexpression of myocardin and Smad1 increased
activation of the ANF promoter reporter ≈5-fold higher than myocardin alone (Figure 2A).
Truncating the ANF promoter to −406 to +70 did not significantly affect the activation by
myocardin alone or the synergy between myocardin and Smad1 (Figure 2A). The −226 to +70
ANF reporter, which excluded 1 of the 2 CArG boxes present within the ANF promoter (CArG-
far, −397 to −77), dramatically decreased the activation of this reporter by myocardin alone
(data not shown); however, the synergy between myocardin and Smad1 was unaffected (Figure
2A). Further deletion of the ANF promoter (−115 to +70) only slightly reduced reporter
activation by myocardin and Smad1 (Figure 2A). Thus, the −115 to +70 region of the ANF
promoter, containing a single CArG box, is sufficient to mediate myocardin/Smad1 synergy.
To test whether the CArG box is required for Smad1 and myocardin functional interaction, the
2 CArG boxes within the ANF promoter luciferase reporter were mutated.1 Whereas myocardin
and Smad1 could synergistically activate the ANF luciferase reporter with a CArG-far
mutation, such synergy was abolished by double CArG mutations (Figure 2A). These data
indicate Smad1 and myocardin functional interaction is CArG-box dependent.
To determine whether the CArG box is sufficient to mediate myocardin/Smad1 synergy, we
used a luciferase reporter controlled by 4 tandem copies of a consensus CArG box.1 Myocardin
alone activated the 4×CArG reporter ≈200-fold, whereas Smad1 and myocardin increased
activation to ≈625-fold (Figure 2B). Thus, we conclude the CArG box is necessary and
sufficient to mediate myocardin and Smad1 synergy.
SBE Is Not Required for Myocardin and Smad1 Synergy
Most Smads weakly interact with DNA through a SBE sequence within the promoter of
responsive genes.32 The ANF −115 to +70 promoter region does not contain a consensus SBE
(AGAC GTCT) but does have 3 AGAC, a half-SBE previously shown to be sufficient for Smad
MH1-domain binding (Figure 3A).33,34 However, Smad1 or Smad4 did not bind to the 3 AGAC
and flanking ≈10 bp by EMSA (data not shown). Mutating the AGAC closest to the TATAA
box (−5 to −2), the only AGAC identified in the promoter region within the −115 to +70 of
the ANF regulatory region (the other 2 are in the 5′ untranslated region of this gene; Figure
3A), did not affect activation by myocardin and Smad1 (Figure 3B). Myocardin and Smad1
synergistically activated a truncated ANF reporter (−115 to −5) where all 3 AGAC sites were
deleted (data not shown), suggesting the SBE site is not required for myocardin and Smad1
synergy. Furthermore, we found that Smad1 did not activate a luciferase reporter controlled
by 6×SBE from SM22, nor could Smad1 synergize with myocardin on this reporter (data not
shown). Finally, we tested whether Smad1 and myocardin could activate the Nkx2.5 promoter
luciferase reporter containing a SBE mutation.29 As shown in Figure 3C, SBE mutation did
not affect the synergy of Smad1 and myocardin. Together, these data demonstrate that Smad1
can synergistically activate cardiac target gene expression with myocardin in a SBE-
independent manner.
Myocardin and Smad1 Interact Directly
We performed coimmunoprecipitation assays to test if myocardin and Smad1 interact directly.
COS7 cells were cotransfected with expression plasmids encoding Flag-tagged Smad1 and
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Myc-tagged myocardin (or singly transfected with each of those constructs in controls). Anti-
Flag antibodies were used to immunoprecipitate Smad1. Anti-Myc antibodies were then used
to detect the presence of associated myocardin. The interaction of myocardin and Smad1 was
detected in lysates prepared from cells expressing both proteins (Figure 4A). Such interaction
was further confirmed using a series of C-terminal deletion myocardin mutants (Figure 4B).
To test whether myocardin and Smad1 interact directly in vitro, we performed GST fusion
protein pull-down assays. GST-Smad1 protein was bacterially expressed and immobilized to
glutathione-agarose beads and incubated with in vitro translated radiolabeled myocardin.
Myocardin specifically interacted with GST-Smad1 but not with GST alone (Figure 4C).
To confirm the specificity of such interaction, as well as to determine the region of myocardin
that mediates Smad1 interaction, we generated a deletion series of GST-myocardin fusion
proteins and tested their interaction with Smad1 by pull-down assay. Radiolabeled Smad1
specifically interacted with amino acids (aa) 1 to 560 and 129 to 689 of myocardin, but not
with GST alone or with aa 382 to 670 or aa 669 to 935 of myocardin (Figure 4D). This result
suggests Smad1 directly interacts with myocardin at a region between aa 129 to 560 (Figure
4E). We have previously identified several conserved domains within this region of myocardin
protein, including the basic domain (aa 243 to 260), Q domain (aa 287 to 320), and SAP domain
(aa 380 to 414). 1,22 We, therefore, tested whether the functional interaction of myocardin and
Smad1 is affected by mutations in those domains by luciferase reporter assay. Basic domain
mutation completely abolished myocardin transactivation as well as its synergy with Smad1
(data not shown). Deletion of the SAP domain or Q domain dramatically decreased the synergy
of myocardin and Smad1 (Figure 4F). The mutations did not alter the expression of those
proteins (Figure 4F). Together, these data demonstrate a direct interaction between myocardin
and Smad1 and suggest such physical interaction is important for their synergistic activation
of cardiac promoters.
Smad Proteins Did Not Directly Affect Formation of the Myocardin/SRF/CArG Complex
Myocardin does not bind to DNA directly, instead it is recruited to target genes by forming a
stable complex with its cofactor SRF bound to DNA element, the CArG box.1 The interaction
of myocardin and Smad1 led us to examine whether Smad1 directly associates with myocardin/
SRF protein complexes bound to CArG box. EMSAs were performed using a radiolabeled
oligonucleotide containing a consensus CArG box. Addition of in vitro translated SRF to the
labeled probe resulted in a specific band (Figure 5, lane 2). Addition of both SRF and Myc-
tagged myocardin resulted in an additional specific band corresponding to the myocardin/SRF/
CArG complex (Figure 5, lane 7). This myocardin/SRF/CArG complex was diminished when
anti-Myc antibodies were added (Figure 5, lane 13), demonstrating it contained myocardin.
Similarly, both SRF and myocardin/SRF complexes were supershifted by anti-SRF antibodies,
demonstrating these complexes contained SRF (Figure 5, lane 14). However, when in vitro
translated Smad1 was added to the incubation mixtures, the SRF/CArG or myocardin/SRF/
CArG complexes were neither supershifted nor diminished (Figure 5, lane 8). A similar result
was obtained despite a several-fold increase in the amount of Smad1 relative to the fixed
amounts of SRF and myocardin (Figure 5, lanes 11 and 12). We also found Smad4 alone or
Smad1 plus Smad4 could not affect the myocardin/SRF/CArG complex (Figure 5, lanes 9 and
10). These results indicate, under the experimental conditions used, Smad1 is not a stable
component of the myocardin/SRF/CArG complex.
Myocardin Activity Is Modulated by BMP Signaling
Interestingly, BMP signaling can be antagonized by inhibitory Smad6 and Smad7.14,15 Smad7
repressed myocardin transactivation of α-CA and ANF promoters in a dose-dependent fashion
(Figure 6A and 6B), presumably by interfering with activation of endogenous BMP-signaling
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components. Constitutively activated ALKs activate BMP signaling in the absence of BMP
ligands.23 To test whether upstream BMP-signaling components stimulate myocardin
transactivity, we used a constitutively activated BMP receptor, ALK3 QD, in luciferase
reporter assays. ALK3 QD stimulated myocardin transactivation of the α-CA and Nkx2.5
reporters (Figure 6C and 6D). Whereas stimulation of myocardin transactivity by ALK3 QD
is comparable to Smads 1 and -4, cotransfection of both ALK3 QD and Smads -1 and -4 with
myocardin further increased the activation of the Nkx2.5 reporter (Figure 6D). Those results
suggest myocardin transactivity is stimulated by BMP signaling originating from the cell
surface.
BMP Signaling Increases Myocardin Protein Expression
BMPs induce the expression of cardiac transcription factor Nkx2.5 and other cardiac markers
in treated chick embryos,18 as well as the P19CL6 cell line.19,20 We asked whether BMPs have
the same effect on myocardin expression. Neonatal rat cardiomyocytes treated with BMP-2
dramatically increased myocardin and MEF2 protein expression, but not of SRF or α-actinin
(Figure 7). BMP-2 did not induce global protein synthesis, as β-tubulin protein expression was
unchanged in BMP-2–treated cardiomyocytes (Figure 7). This result demonstrates BMP
signaling induces myocardin expression in cardiomyocytes and suggests a positive feedback
mechanism for BMP signaling and myocardin to activate cardiac genes.
Discussion
In this report, we identified the molecular interaction of myocardin and the BMP-signaling
pathway to synergistically activate cardiac gene expression. Along with the accompanying
study demonstrating that myocardin and TGF-β–signaling pathway synergistically activate SM
gene expression,35 our results clearly establish that myocardin is involved in TGF-β
superfamily signaling pathways that regulate cardiac and SM-specific gene expression.
Transactivation of Cardiac Gene Expression by Myocardin and BMP Signaling
We have recently uncovered several mechanisms by which myocardin regulates cardiac and
SM gene expression. GATA4 represses or activates myocardin-mediated transactivation,
depending on the specificity of target genes.36 Myocardin transactivity is also positively and
negatively regulated by p300 and HDAC5, suggesting an additional layer of regulation at the
chromatin level.12 Interestingly, myocardin is also involved in a molecular switch controlling
SRF-dependent cell differentiation versus proliferation processes, where myocardin directly
competes with Elk1 for SRF association and target gene activation.13 Together, those studies
indicate the transcriptional activity of myocardin is tightly controlled.
In this study, we demonstrated myocardin transactivation of cardiac gene expression is
modulated by BMP signaling through a protein–protein interaction between myocardin and
BMP-downstream effector Smad1, providing another novel mechanism in which myocardin
is integrated into an important signaling pathway to regulate gene expression. Most
importantly, we found the BMP signaling was also able to induce expression of myocardin,
suggesting a potential positive-feedback mechanism. This mechanism could be used where
both myocardin and BMP initiate early cardiac gene expression, whereas myocardin is later
used for the maintenance of the cardiac program. Interestingly, such mechanisms exist in
skeletal muscle and other biological systems.37,38
SBE Dependency or SBE Independency?
The synergy between Smad1 and myocardin in activating the ANF promoter appears to be SBE
independent. Those results were distinct from the response of Smad3 and myocardin, which
synergistically activate a SBE-controlled reporter.35 In contrast, myocardin and Smad1
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synergistically activated a luciferase reporter driven by 4 CArG box copies, where absolutely
no SBE is involved. These data suggest Smad1 can activate cardiac gene expression
independently of inherent DNA binding. Similar SBE-independent mechanisms have been
recently reported for a variety of target genes regulated by BMP/Smads.39–41
Then how does Smad1 activate target gene expression independent of DNA binding? Several
mechanisms may apply: Smad1 could be recruited by myocardin and SRF to the CArG boxes
in the ANF promoter. However, whereas we detected protein–protein interaction between
myocardin and Smad1 in vitro and in vivo, we were unable to obtain evidence for the formation
of a potential ternary complex among those proteins bound to DNA under our experimental
conditions. Interestingly, some SRF cofactors are suggested to enhance the affinity of SRF/
DNA association, despite not forming a stable ternary complex with SRF bound to DNA.3,42
Our data suggest that Smad1 enhances the activity of the myocardin/SRF transcriptional
complex through alternative mechanisms. Those include the recruitment of coactivators, such
as p300, or by repelling transcriptional repressors from this transcriptional complex. It will be
important to investigate how the physical and functional interaction of endogenous Smad1 and
myocardin proteins is influenced by BMP signaling, as we cannot rule out the possibility that
Smad1 might affect myocardin/SRF/CArG–complex formation in a BMP–dependent manner.
Cardiac or Smooth Muscle?
Myocardin is a cardiac and SM-specific transcriptional cofactor for SRF and activates target
gene expression in a CArG-dependent manner.1,3 It is currently unclear how myocardin
discriminates between cardiac and SM target genes, although the SAP domain has been
suggested to be involved.1 In this study, we showed myocardin and Smad1 interact directly to
synergistically activate cardiac reporter gene expression. Such activation requires the CArG
box and appears to be SBE independent. Additionally, the functional interaction between
myocardin and Smad1 was completely abolished in SRF-null embryonic stem cells (T.E.C.
and D.-Z.W., unpublished data, 2005), further supporting the notion of CArG box/SRF
dependency. We suggest the target specificity (cardiac versus SM) for myocardin is
determined, at least in part, by which upstream signals, TGF-β or BMP, and their downstream
effectors, Smad3 or Smad1, are used. This hypothesis is consistent with the notion that BMPs
are key regulators for cardiac gene expression, whereas TGF-β appears to play a significant
role in controlling SMC gene expression.16,43,44 Interestingly, the SAP domain of myocardin
appears involved in mediating the functional interaction between myocardin and Smad1
because SAP domain mutation dramatically decreased the synergy of myocardin and Smad1
on a CArG-box–dependent reporter gene (Figure 4E). Together, our data suggest the SAP
domain of myocardin may serve as a nodal point to integrate BMP-signaling pathway in
activating myocardin-mediated cardiac gene expression. Future investigation, in particular in
vivo studies, will be needed to further clarify this issue. Nevertheless, our studies establish a
direct molecular and functional interaction between myocardin and BMP signaling and suggest
a molecular mechanism for the transcriptional regulation of the cardiac gene program. Given
the importance of myocardin and BMPs, it is intriguing to speculate that mutations in either
molecule or disruption of their functional interaction may contribute to human cardiovascular
diseases.
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Synergistic activation of cardiac promoters by myocardin and Smad1. Luciferase reporters
controlled by ANF (A), α-MHC (B), MLC2V (C), α-CA (D), and Nkx2.5 (E) promoters were
transfected into COS7 cells with Smad1 and/or myocardin expression plasmids. F, COS7 cells
were transfected with UAS-luciferase reporter and/or GAL4-Smad1 and myocardin (400 and
800 ng as indicated) expression plasmids. G, Cardiomyocytes were transfected with ANF
luciferase reporter with Smad1 and/or myocardin expression plasmids. Values are the fold
increase in luciferase activity relative to activation of the reporter alone. Error bars represent
SD of at least 2 experiments. Student’s t test: *P<0.05, myocardin alone vs myocardin plus
Smad1.
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CArG box is necessary and sufficient to mediate myocardin and Smad1 synergy. A, COS7
cells were transfected with the indicated ANF promoter luciferase reporters and/or myocardin
and Smad1 expression plasmids. Values are the fold increase of luciferase activity by
myocardin and Smad1 (black bars) relative to luciferase activity by myocardin alone (gray
bars), which is assigned the value of 1. B, Luciferase reporter controlled by 4 copies of a
consensus CArG box was transfected into COS7 cells with myocardin and/or Smad1
expression plasmids. Values are the fold increase in luciferase activity relative to activation of
the reporter alone. Error bars represent SD of at least 2 experiments. Student’s t test: *P<0.05,
myocardin alone vs myocardin plus Smad1.
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SBE is not required for myocardin and Smad1 synergy. A, DNA sequence of the −115 to +70
region of the ANF promoter. Underlined are CArG-near, TATA box, the mutated half-SBE
site, and 2 other half-SBE sites (AGAC) within the 5′ untranslated region. B, Luciferase
reporters controlled by the ANF promoter (gray bars) or the ANF promoter with mutated half-
SBE (black bars) were transfected into COS7 cells with myocardin and/or Smad1 expression
plasmids. C, Luciferase reporter controlled by the Nkx2.5 promoter containing SBE mutations
was transfected into COS7 cells with myocardin and/or Smad1 expression plasmids. Values
are the fold increase in luciferase activity relative to activation of the reporter alone. Error bars
represent SD of at least 2 experiments. Student’s t test: *P<0.05, myocardin alone vs myocardin
plus Smad1.
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Myocardin and Smad1 interact directly. A, Myocardin coimmunoprecipitates with Smad1.
COS7 cells were transfected with plasmids encoding Flag-tagged Smad1 and/or Myc-tagged
myocardin, as indicated. Smad1 was immunoprecipitated by (IP) anti-Flag antibodies, and anti-
Myc antibodies were used to detect the presence of myocardin in the immunoprecipitates by
Western blot (WB) analysis (top). One-fifteenth of cell extracts were directly immunoblotted
to detect the presence of myocardin and Smad1 proteins (middle panels). One-fifteenth of
supernatants (after immunoprecipitation) were immunoblotted to detect myocardin proteins
(bottom). B, Myc-tagged myocardin aa 1 to 274 (M1), aa 1 to 351 (M2), and aa 1 to 421 (M3)
were detected in Flag-Smad1 immunoprecipitates (top). Ten percent of cell extracts were
directly immunoblotted to detect the presence of truncated myocardin proteins or Smad1
(middle panels). One-fifteenth of supernatants (after immunoprecipitation) were
immunoblotted to detect truncated myocardin proteins (bottom). C, Myocardin specifically
interacted with GST-Smad1 but not with GST alone. Coomassie-stained proteins
corresponding to the amount of GST and GST-Smad1 protein used in the pull-down assay are
shown below the autoradiograph, and 5% of the input protein is shown at left. D, Smad1
interacts with GST fused to myocardin aa 1 to 560 and aa 129 to 689 but not with aa 328 to
670, nor aa 669 to 935, nor with GST alone. Coomassie-stained proteins corresponding to the
amounts of GST and GST-myocardin protein used in the pull-down assay are shown directly
below the autoradiograph, and 1% of the input protein is shown at left. E, Myocardin and
Smad1 interaction summary. Myocardin domains are abbreviated as follows: NTD indicates
amino-terminal domain;++, basic domain; Q, a stretch of glutamine residues; SAP, SAF A/B,
Acinus, PIAS domain; TAD, transactivation domain. F, Luciferase reporter controlled by 4
copies of a consensus CArG box and expression plasmids for myocardin, myocardin ΔSAP
domain, or myocardin ΔQ domain and/or Smad1 was transfected into COS7 cells. Values are
the luciferase activity by myocardin or myocardin mutants and Smad1 (black bars) relative to
the activation of reporter by myocardin alone or myocardin mutants (gray bars). Error bars
represent SD of at least 2 experiments. Student’s t test: *P<0.05, myocardin alone vs myocardin
plus Smad1. Myc-tagged myocardin, myocardin ΔSAP, and myocardin ΔQ protein expressions
are shown by Western blot.
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Smad proteins did not affect the formation of the myocardin/SRF/CArG complex. SRF, Myc-
tagged myocardin, and Flag-tagged Smad1 and Smad4 proteins were translated in vitro and
incubated with radiolabeled CArG probe, as described in Materials and Methods. Protein–
DNA complexes were separated by nondenaturing PAGE and analyzed by autoradiography.
Asterisk indicates nonspecific band.
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Myocardin activity is modulated by BMP signaling. Myocardin and/or Smad7 (100, 150, and
200 ng) expression plasmids and α-CA (A) or ANF (B) luciferase reporter were transfected
into COS7 cells. Values are the percentage of luciferase activity relative to activation of the
reporter by myocardin alone. C, α-CA or Nkx2.5 luciferase reporter, Smads 1 and -4, ALK3
QD, and/or myocardin expression plasmids were transfected into COS7 cells. Values are the
fold increase in luciferase activity relative to activation of the reporter alone. Error bars
represent SD of at least 2 experiments. Student’s t test; P<0.05: *myocardin alone vs myocardin
plus Smad7, Smad1/4, or ALK3 QD; **myocardin alone vs myocardin plus Smad1/4 and
ALK3 QD.
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Myocardin protein level is increased in BMP-2–treated cardiomyocytes. Rat neonatal
cardiomyocytes were treated with 20 ng/mL BMP-2 (or without in negative control) for 48
hours before harvesting and lysate production for SDS-PAGE and Western Blot analysis with
indicated antibodies, as described in Materials and Methods.
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